14-day Premium Trial Subscription Try For FreeTry Free

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of VKTX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Tuesday for Viking Therapeutics
(Updated on May 07, 2024)

Buy or Hold candidate since Apr 26, 2024 Gain 7.13% PDF

The Viking Therapeutics stock price gained 1.79% on the last trading day (Tuesday, 7th May 2024), rising from $78.21 to $79.61. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 6.99% from a day low at $76.51 to a day high of $81.86. The price has risen in 8 of the last 10 days and is up by 22.61% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 568 thousand more shares were traded than the day before. In total, 4 million shares were bought and sold for approximately $289.07 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 36.80% during the next 3 months and, with a 90% probability hold a price between $83.63 and $163.99 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

VKTX Signals & Forecast

The Viking Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $77.43 and $72.73. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, February 28, 2024, and so far it has fallen -15.76%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for Viking Therapeutics stock

Viking Therapeutics finds support from accumulated volume at $77.05 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $5.35 between high and low, or 6.99%. For the last week, the stock has had daily average volatility of 6.93%.

Our recommended stop-loss: $75.22 (-5.52%) (This stock has high daily movements and this gives high risk. There is a sell signal from a pivot top found 48 days ago.)

Trading Expectations (VKTX) For The Upcoming Trading Day Of Wednesday 8th

For the upcoming trading day on Wednesday, 8th we expect Viking Therapeutics to open at $79.33, and during the day (based on 14 day Average True Range), to move between $74.63 and $84.59, which gives a possible trading interval of +/-$4.98 (+/-6.26%) up or down from last closing price. If Viking Therapeutics takes out the full calculated possible swing range there will be an estimated 12.51% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $80.83 (1.53%) than the support at $77.05 (3.22%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Viking Therapeutics stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Viking Therapeutics stock to perform well in the short-term.

Current score: 4.686 Buy Candidate Unchanged

Predicted Opening Price for Viking Therapeutics of Wednesday, May 8, 2024

Fair opening price May 8, 2024 Current price
$79.33 ( 0.356%) $79.61

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for VKTX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 84.68 6.36 %
R2 82.63 3.80 %
R1 81.37 2.21 %
Current price: 79.61
Support S1 77.28 -2.92 %
S2 76.02 -4.51 %
S3 73.98 -7.08 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 94.50 18.70 %
R2 85.05 6.83 %
R1 80.83 1.53 %
Current price 79.61
Support S1 77.05 -3.22%
S2 74.00 -7.05%
S3 71.78 -9.84%

FAQ

What is the symbol for Viking Therapeutics Stock and on which exchange is it traded?
The symbol for Viking Therapeutics is VKTX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Viking Therapeutics Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Viking Therapeutics stock to perform well in the short-term.

How to buy Viking Therapeutics Stock?
Viking Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Viking Therapeutics Stock.

What's the current price of Viking Therapeutics Stock?
As of the end of day on the May 07, 2024, the price of an Viking Therapeutics (VKTX) share was $79.61.

What is the 52-week high and low for Viking Therapeutics Stock?
The 52-week high for Viking Therapeutics Stock is $14.69 and the 52-week low is $12.16.

What is the market capitalization of Viking Therapeutics Stock?
As of the May 07, 2024, the market capitalization of Viking Therapeutics is 8.624B.

When is the next earnings date for Viking Therapeutics?
The upcoming earnings date for Viking Therapeutics is Jul 24, 2024.
Click to get the best stock tips daily for free!

About Viking Therapeutics

Viking Therapeutics Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also dev... VKTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT